Patient characteristics and distribution of common risk factors
| . | All patients . | Donor LCT −13910 CC . | Donor LCT −13910 TC or TT . | P . |
|---|---|---|---|---|
| Number in group (%) | 111 | 30 (27.0) | 81 (73.0) | |
| Patients' mean age, y, (± SD) | 41.7 (± 12.5) | 44.4 (± 11.3) | 40.7 (± 12.8) | .170 |
| Younger than 40 y, n (%) | 50 (45.0) | 10 (33.3) | 40 (49.4) | .141 |
| Older than 40 y, n (%) | 61 (55.0) | 20 (66.7) | 41 (50.6) | |
| Sex, n (%) | .0 | |||
| Male | 60 (54.1) | 18 (60.0) | 42 (51.9) | .444 |
| Female | 51 (45.9) | 12 (40.0) | 39 (48.1) | |
| Conditioning regimen, n (%) | ||||
| Myeloablative | 70 (63.1) | 17 (56.7) | 53 (65.4) | .395 |
| Reduced intensity | 41 (36.9) | 13 (43.3) | 28 (34.6) | |
| Source of stem cells, n (%) | ||||
| Bone marrow | 8 (7.2) | 2 (6.7) | 6 (7.4) | 1.000 |
| Peripheral blood stem cells | 103 (92.8) | 28 (93.3) | 75 (92.6) | |
| Stage of disease, n (%) | ||||
| Early* | 41 (36.9) | 11 (36.7) | 30 (37.0) | .971 |
| Advanced† | 70 (63.1) | 19 (63.3) | 51 (63.0) | |
| Diagnosis, n (%) | ||||
| Acute leukemia | 69 (62.2) | 20 (66.7) | 49 (60.5) | .621 |
| Chronic myeloid disorder | 20 (18.0) | 5 (16.7) | 15 (18.5) | |
| Lymphoma | 14 (12.6) | 2 (6.7) | 12 (14.8) | |
| Other | 8 (7.2) | 3 (10.0) | 5 (6.2) | |
| Type of donor, n (%) | ||||
| HLA identical sibling | 87 (78.4) | 20 (66.7) | 67 (82.7) | .068 |
| Other donor (mismatch and/or UD) | 24 (21.6) | 10 (33.3) | 14 (17.3) | |
| Donors' mean age, y (± SD) | 40.9 (± 12.9) | 40.0 (± 14.3) | 41.3 (± 12.5) | .637 |
| Younger than 40 y, n (%) | 51 (45.9) | 14 (46.7) | 37 (45.7) | .926 |
| Older than 40 y, n (%) | 60 (54.1) | 16 (53.3) | 44 (54.3) | |
| Donor/recipient sex, n (%) | ||||
| Female/male | 21 (18.9) | 5 (16.7) | 16 (19.8) | .712 |
| Other combination | 90 (81.1) | 25 (83.3) | 65 (80.2) | |
| Recipient/donor CMV status, n (%)‡ | ||||
| Positive/negative | 17 (16.5) | 6 (20.7) | 11 (14.9) | .474 |
| Other combination | 86 (83.5) | 23 (79.3) | 63 (85.1) | |
| CD 34+ cells infused, 106/kg (± SD) | 4.7 (± 2.3) | 5.0 (± 2.4) | 4.5 (± 2.3) | .362 |
| Recipient LCT −13910 genotype, n (%) | ||||
| TT | 32 (28.8) | 4 (13.3) | 28 (34.6) | <.001 |
| TC | 59 (53.2) | 13 (43.3) | 46 (56.8) | |
| CC | 20 (18.0) | 13 (43.3) | 7 (8.6) |
| . | All patients . | Donor LCT −13910 CC . | Donor LCT −13910 TC or TT . | P . |
|---|---|---|---|---|
| Number in group (%) | 111 | 30 (27.0) | 81 (73.0) | |
| Patients' mean age, y, (± SD) | 41.7 (± 12.5) | 44.4 (± 11.3) | 40.7 (± 12.8) | .170 |
| Younger than 40 y, n (%) | 50 (45.0) | 10 (33.3) | 40 (49.4) | .141 |
| Older than 40 y, n (%) | 61 (55.0) | 20 (66.7) | 41 (50.6) | |
| Sex, n (%) | .0 | |||
| Male | 60 (54.1) | 18 (60.0) | 42 (51.9) | .444 |
| Female | 51 (45.9) | 12 (40.0) | 39 (48.1) | |
| Conditioning regimen, n (%) | ||||
| Myeloablative | 70 (63.1) | 17 (56.7) | 53 (65.4) | .395 |
| Reduced intensity | 41 (36.9) | 13 (43.3) | 28 (34.6) | |
| Source of stem cells, n (%) | ||||
| Bone marrow | 8 (7.2) | 2 (6.7) | 6 (7.4) | 1.000 |
| Peripheral blood stem cells | 103 (92.8) | 28 (93.3) | 75 (92.6) | |
| Stage of disease, n (%) | ||||
| Early* | 41 (36.9) | 11 (36.7) | 30 (37.0) | .971 |
| Advanced† | 70 (63.1) | 19 (63.3) | 51 (63.0) | |
| Diagnosis, n (%) | ||||
| Acute leukemia | 69 (62.2) | 20 (66.7) | 49 (60.5) | .621 |
| Chronic myeloid disorder | 20 (18.0) | 5 (16.7) | 15 (18.5) | |
| Lymphoma | 14 (12.6) | 2 (6.7) | 12 (14.8) | |
| Other | 8 (7.2) | 3 (10.0) | 5 (6.2) | |
| Type of donor, n (%) | ||||
| HLA identical sibling | 87 (78.4) | 20 (66.7) | 67 (82.7) | .068 |
| Other donor (mismatch and/or UD) | 24 (21.6) | 10 (33.3) | 14 (17.3) | |
| Donors' mean age, y (± SD) | 40.9 (± 12.9) | 40.0 (± 14.3) | 41.3 (± 12.5) | .637 |
| Younger than 40 y, n (%) | 51 (45.9) | 14 (46.7) | 37 (45.7) | .926 |
| Older than 40 y, n (%) | 60 (54.1) | 16 (53.3) | 44 (54.3) | |
| Donor/recipient sex, n (%) | ||||
| Female/male | 21 (18.9) | 5 (16.7) | 16 (19.8) | .712 |
| Other combination | 90 (81.1) | 25 (83.3) | 65 (80.2) | |
| Recipient/donor CMV status, n (%)‡ | ||||
| Positive/negative | 17 (16.5) | 6 (20.7) | 11 (14.9) | .474 |
| Other combination | 86 (83.5) | 23 (79.3) | 63 (85.1) | |
| CD 34+ cells infused, 106/kg (± SD) | 4.7 (± 2.3) | 5.0 (± 2.4) | 4.5 (± 2.3) | .362 |
| Recipient LCT −13910 genotype, n (%) | ||||
| TT | 32 (28.8) | 4 (13.3) | 28 (34.6) | <.001 |
| TC | 59 (53.2) | 13 (43.3) | 46 (56.8) | |
| CC | 20 (18.0) | 13 (43.3) | 7 (8.6) |